|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Lesion volume****vs** | **rs** | ***p*-value** |
| **GBM** | **vsi** | 0.5021337 | 0.001761\*\* |
| **Q** | -0.5315465 | 0.0007106\*\*\* |
| **CBV** | 0.173542 | 0.3031 |
| **CBF** | 0.1095306 | 0.5173 |
| **ADC** | -0.09685833 | 0.5685 |
| **PCNSL** | **vsi** | 0.1368187 | 0.4693 |
| **Q** | -0.08031146 | 0.6721 |
| **CBV** | 0.2111235 | 0.2616 |
| **CBF** | 0.3259177 | 0.07925 |
| **ADC** | -0.01490711 | 0.9377 |
| **MLC** | **vsi** | 0.2797203 | 0.3787 |
| **Q** | -0.4965035 | 0.1041 |
| **CBV** | -0.01398601 | 0.9737 |
| **CBF** | -0.02097902 | 0.9562 |
| **ADC** | 0.0979021 | 0.7663 |

**Supplementary Table 1.** Summary of the Spearman correlation coefficient analysis results between tumor volumes vs VSI, perfusion, and diffusion parameters. GBM: Glioblastoma multiforme; PCNSL: Primary CNS Lymphoma; MLC: Metastatic Lung Cancer; vsi: vessel size index; Q: microvessel density; CBV: cerebral blood volume; CBF: cerebral blood flow; ADC: apparent diffusion coefficient; rs: Spearman's rank correlation coefficient; \*\**p*<0.01, \*\*\**p*<0.001.